AELIX Therapeutics is a clinical stage biotechnology company based in Barcelona, Spain, focused on the development of a therapeutic HIV vaccine to be used in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in the field of AIDS. The HIVACAT programme, which aims to develop strategies to prevent and cure HIV and AIDS, is led by IrsiCaixa Aids Research Institute and the Infectious Diseases and AIDS Unit of the Hospital Clínic of Barcelona. The HIVACAT consortium licensed the HTI technology to AELIX Therapeutics for its global development and commercialization. The company was incorporated in November 2015 and completed a €11.5M ($12.5M) Series A funding shortly thereafter through funds managed by Ysios Capital, a Spanish investment firm, Johnson & Johnson – JJDC, Inc., and Caixa Capital Risc, the venture capital division of Spain’s leading group, “la Caixa”.